RICHMOND, Calif., Jan. 8, 2018 /PRNewswire/ -- In
meetings with investors this week and during a presentation
Wednesday at the J.P. Morgan Healthcare Conference in San Francisco, Sangamo Therapeutics, Inc.
(NASDAQ: SGMO) Chief Executive Officer, Dr. Sandy Macrae will review the Company's growth
and recent progress and outline key priorities and catalysts for
the coming year.
"Last year we made significant progress transitioning Sangamo
from its previous research focus to a sustainable, fully integrated
company that aims to translate cutting edge science into genomic
medicines to transform patients' lives," said Dr. Macrae. "With new
management, a clear strategy, the validation of external
collaborations, a strengthened balance sheet – and with core values
that make the patient the central focus of everything we do –
Sangamo is now operating with urgency and efficiency to pursue the
vast opportunities presented by our technology platform."
Dr. Macrae continued: "We expect a transformative 2018 with key
proof-of-concept data for in vivo genome editing and gene
therapy clinical programs. Building on last year's foundation, we
will also progress our middle pipeline into the clinic, advance our
novel delivery platforms and pursue new strategic collaborations
combining Sangamo's technology with external expertise and
resources for select therapeutic applications."
Sangamo will provide 2018 financial guidance when the Company
reports fourth quarter and full year 2017 business and financial
results later this quarter. Sangamo expects that available cash
resources will be sufficient to fund currently planned operations
for at least the next two years.
Sangamo will be participating in the 36th Annual J.P.
Morgan Healthcare Conference being held in San Francisco from January 8th to 11th. Dr.
Sandy Macrae, Sangamo's CEO, is
scheduled to present on Wednesday, January
10, 2018 at 4:00 p.m. PT. The
presentation will be followed by a separate Q&A session
starting at 4:30 p.m. PT. A live
webcast of Dr. Macrae's presentation and the Q&A session will
be accessible through a link on the Investors and Media section of
the company's website, under Events and Presentations.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc.
is focused on translating ground-breaking science into genomic
therapies that transform patients' lives using the company's
industry leading platform technologies in genome editing, gene
therapy, gene regulation and cell therapy. The Company is
conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia
B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an
exclusive, global collaboration and license agreement with Pfizer
Inc. for gene therapy programs for Hemophilia A and gene regulation
programs for C9ORF72-linked amyotrophic lateral sclerosis and
frontotemporal lobar degeneration; with Bioverativ Inc. for
hemoglobinopathies, including beta thalassemia and sickle cell
disease; and with Shire International GmbH to develop therapeutics
for Huntington's disease. In addition, it has established strategic
partnerships with companies in non-therapeutic applications of its
technology, including Sigma-Aldrich Corporation and Dow
AgroSciences. For more information about Sangamo, visit the
Company's website at www.sangamo.com.
Cautionary Statement regarding Forward-Looking
Statements
This press release contains forward-looking
statements based on Sangamo's current expectations. These
forward-looking statements include, without limitation, expected
cash and cash equivalents as of the year ended December 31, 2017, the ability of Sangamo to
pursue opportunities presented by Sangamo's technology
platform, the expectation and timing of key proof-of-concept data
for in vivo genome editing and gene therapy clinical programs, the
ability of Sangamo to progress its product candidates into the
clinic or develop and progress other product candidates in the
pipeline, and the ability to pursue new strategic
collaborations. Actual results may differ materially
from these forward-looking statements due to a number of factors,
including differences in the actual level of cash and cash
equivalents after completion of the year-end accounting process;
uncertainties relating to the ability of Sangamo to execute on its
strategic plan in pursuing opportunities with Sangamo's technology
platform, the inability to execute on Sangamo's corporate strategy
to partner with other pharmaceutical companies or collaborate
successfully, and the risk that the data from Sangamo's ongoing
clinical trials may not provide proof-of-concept validation or
warrant further development and advancement of its product
candidates, or that the results of such trials may be delayed. For
a more detailed discussion of these and other risks, please see
Sangamo's SEC filings, including the risk factors described in its
most recent Quarterly Report on Form 10-Q. Sangamo assumes no
obligation to update the forward-looking information contained in
this press release.
View original content with
multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-outlines-2018-key-priorities-and-catalysts-at-jp-morgan-healthcare-conference-300578813.html
SOURCE Sangamo Therapeutics, Inc.